ABSTRACT
Telangiectatic osteosarcoma is a rare variant of osteosarcoma. In the original report from the authors' institution, a poor prognosis was noted. The authors have updated their experience with this entity. The prognosis for patients with telangiectatic osteosarcoma has improved remarkably. The prognosis in the present series seems to be the same as that for conventional osteosarcoma. Adjuvant chemotherapy seems to help in salvaging patients with metastatic disease. However, in this small series, survival of patients without metastasis is apparently not influenced by whether they received chemotherapy.
Subject(s)
Amputation, Surgical/standards , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/therapy , Osteosarcoma/therapy , Telangiectasis/therapy , Adolescent , Adult , Bone Neoplasms/mortality , Bone Neoplasms/pathology , Child , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Male , Middle Aged , Minnesota/epidemiology , Neoplasm Metastasis , Osteosarcoma/mortality , Osteosarcoma/pathology , Prognosis , Survival Rate , Telangiectasis/mortality , Telangiectasis/pathologyABSTRACT
The Virogen CMV Antibody Test and Difco CMV-Cube were compared with three other available methods, enzyme immunoassay, immunofluorescence and latex agglutination, for the detection of cytomegalovirus (CMV) antibody in 126 random sera submitted to the clinical laboratory. Based on concordance of three or more methods, 72% of the samples were positive for CMV antibody. The sensitivities and specificities of the assays were Virogen, 98% and 97%, and CMV-Cube 97% and 97%, respectively.
